{"id":4345,"date":"2022-03-15T13:46:19","date_gmt":"2022-03-15T13:46:19","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=4345"},"modified":"2022-03-15T13:46:19","modified_gmt":"2022-03-15T13:46:19","slug":"mariana-c-castells-md-aaaai-22-a-phase-2-3-study-of-blu-263-in-patients-with-indolent-systemic-mastocytosis-or-monoclonal-mast-cell-activation-syndrome","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/dermatological-conditions\/conference-hub\/mariana-c-castells-md-aaaai-22-a-phase-2-3-study-of-blu-263-in-patients-with-indolent-systemic-mastocytosis-or-monoclonal-mast-cell-activation-syndrome\/","title":{"rendered":"Mariana C. Castells, MD, AAAAI 22: A Phase 2\/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome."},"content":{"rendered":"

It was an absolute pleasure to speak with <\/span>Prof. Mariana Castells<\/b> (Brigham and Women’s Hospital, Boston, MA) about her study of BLU-263 and how it is supporting continued development for patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome.<\/span><\/p>\n

The abstract entitled \u2018A Phase 2\/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome\u2019 (Abstract #665) was presented at <\/span>The American Academy of Allergy, Asthma & Immunology (AAAAI)<\/span><\/a>, February 25-28, 2022<\/span><\/p>\n

Questions:<\/b><\/p>\n

    \n
  1. What is BLU-263 and what is the rationale for its use in this patient population?(0:25)<\/span><\/li>\n
  2. What are the aims and design of the HARBOR study?(02:26)<\/span><\/li>\n
  3. What are the eligibility criteria of the study?(03:51)<\/span><\/li>\n
  4. When are the initial results expected?(05:12)<\/span><\/li>\n<\/ol>\n

    Disclosures: <\/b>Mariana Castells has nothing to disclose in relation to this video.<\/span><\/p>\n

    Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.<\/b><\/p>\n

    Filmed in coverage of the virtual AAAAI 2022.<\/b><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    It was an absolute pleasure to speak with Prof. Mariana Castells (Brigham and Women’s Hospital, Boston, MA) about her study of BLU-263 and how it is supporting continued development for patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome. The abstract entitled \u2018A Phase 2\/3 Study of BLU-263 in Patients with Indolent Systemic […]<\/p>\n","protected":false},"featured_media":4347,"template":"","class_list":["post-4345","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-dermatological-conditions","video_categories-aaaai-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/4345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/4345\/revisions"}],"predecessor-version":[{"id":4349,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/4345\/revisions\/4349"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/4347"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=4345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}